This prospective single-arm clinical trial demonstrated that 177Lu-PSMA-I&T RLT achieve favourable response and significantly improved QOL in East Asian patients with mCRPC with well tolerance, which associates with significant PSA decline and tumor remission including adenopathy and bone metastasis. This evidence concerns the gene KLK3 and bone metastasis.